Verrica Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Verrica Pharmaceuticals Inc VRCA.OQ reported quarterly adjusted earnings of 2 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.70. The mean expectation of five analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from -71 cents to -70 cents per share.

• Revenue rose 145.4% to $12.70 million from a year ago; analysts expected $4.27 million.

• Verrica Pharmaceuticals Inc's reported EPS for the quarter was 2 cents​.

• The company reported quarterly net income of $204 thousand.

• Verrica Pharmaceuticals Inc shares had risen by 26.4% this quarter and lost 4.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 14.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $40.00, about 83.2% above its last closing price of $6.70

This summary was machine generated from LSEG data August 12 at 08:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)